Skip to main content
Premium Trial:

Request an Annual Quote

Psychiatric Genomics Closes on $6M Funding

NEW YORK, Sept. 10 (GenomeWeb News) - Psychiatric Genomics of Gaithersburg, Md., today announced the closing of $6 million in financing from the Stanley Medical Research Institute of Bethesda, Md., a non-profit research organization.

 

Michael Knable, executive director of the investor, will join the Psychiatric Genomics board of directors in addition to the post he holds on the company's scientific advisory board, Psychiatric Genomics said in a statement. Previously, SMRI invested $1 million in the company's Series B financing in November 2002.

 

Psychiatric Genomics will use the funds to identify gene expression patterns for use in creating compounds to treat psychiatric diseases, the company said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.